{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:09:58Z","timestamp":1778695798766,"version":"3.51.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Yao Yu","award":["PL2024H120"],"award-info":[{"award-number":["PL2024H120"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03185-3","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T09:58:36Z","timestamp":1766743116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-tumor effects and mechanism of the histone demethylase inhibitor GSK-J4 in non-small cell lung cancer cells"],"prefix":"10.1007","volume":"43","author":[{"given":"Dandan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menghan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danting","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"3","key":"3185_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3185_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"3185_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jtho.2020.10.155","volume":"16","author":"YH Luo","year":"2021","unstructured":"Luo YH, Chiu CH, Scott Kuo CH, Chou TY, Yeh YC, Hsu HS, et al. Lung cancer in Republic of China. J Thorac Oncol. 2021;16(4):519\u201327.","journal-title":"J Thorac Oncol"},{"issue":"7689","key":"3185_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354.","journal-title":"Nature"},{"issue":"8","key":"3185_CR5","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina JR. Non-Small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623\u201340.","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"3185_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7(12):1824\u201332.","journal-title":"JAMA Oncol"},{"issue":"8","key":"3185_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345\u201356.","journal-title":"Nat Med"},{"issue":"28","key":"3185_CR8","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C. etal. Five-Year overall survival for patients with advanced Non\u2013Small-Cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518\u201327.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3185_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s11033-025-10447-w","volume":"52","author":"J Obradovi\u0107","year":"2025","unstructured":"Obradovi\u0107 J, Ni\u0161evic-Lazovi\u0107 J, Sekeru\u0161 V, Mila\u0161in J, Perin B, Jurisic V. Investigating the frequencies of EGFR mutations and EGFR single nucleotide polymorphisms genotypes and their predictive role in NSCLC patients in Republic of Serbia. Mol Biol Rep. 2025;52(1):350.","journal-title":"Mol Biol Rep"},{"key":"3185_CR10","doi-asserted-by":"publisher","first-page":"1973241","DOI":"10.1155\/2020\/1973241","volume":"2020","author":"V Jurisic","year":"2020","unstructured":"Jurisic V, Vukovic V, Obradovic J, Gulyaeva LF, Kushlinskii NE, Djordjevi\u0107 N. EGFR polymorphism and survival of NSCLC patients treated with tkis: A systematic review and Meta-Analysis. J Oncol. 2020;2020:1973241.","journal-title":"J Oncol"},{"key":"3185_CR11","first-page":"6192187","volume":"2018","author":"V Juri\u0161i\u0107","year":"2018","unstructured":"Juri\u0161i\u0107 V, Obradovic J, Pavlovi\u0107 S, Djordjevic N. Epidermal growth factor receptor gene in Non-Small-Cell lung cancer: the importance of promoter polymorphism investigation. Anal Cell Pathol (Amst). 2018;2018:6192187.","journal-title":"Anal Cell Pathol (Amst)"},{"issue":"2","key":"3185_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3892\/ol.2022.13649","volume":"25","author":"J Obradovic","year":"2022","unstructured":"Obradovic J, Todosijevic J, Jurisic V. Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis. Oncol Lett. 2022;25(2):62.","journal-title":"Oncol Lett"},{"issue":"10","key":"3185_CR13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/bies.1132","volume":"23","author":"P Savagner","year":"2001","unstructured":"Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 2001;23(10):912\u201323.","journal-title":"Bioessays"},{"issue":"34","key":"3185_CR14","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741\u201351.","journal-title":"Oncogene"},{"issue":"1","key":"3185_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12943-017-0700-1","volume":"16","author":"S Yang","year":"2017","unstructured":"Yang S, Liu Y, Li MY, Ng CSH, Yang SL, Wang S, Zou C, Dong Y, Du J. etal. FOXP3 promotes tumor growth and metastasis by activating Wnt\/\u03b2-catenin signaling pathway and EMT in non-small cell lung cancer. Mol Cancer. 2017;16(1):124.","journal-title":"Mol Cancer"},{"issue":"6","key":"3185_CR16","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/ijc.34559","volume":"153","author":"N Dalpatraj","year":"2023","unstructured":"Dalpatraj N, Naik A, Thakur N. GSK-J4: an H3K27 histone demethylase inhibitor, as a potential anti-cancer agent. Int J Cancer. 2023;153(6):1130\u20138.","journal-title":"Int J Cancer"},{"issue":"1","key":"3185_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"1","key":"3185_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1462-y","volume":"38","author":"S Zhang","year":"2019","unstructured":"Zhang S, Zhang F, Chen Q, et al. CRISPR\/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1\/H3\/Wnt10b signaling pathway. J Exp Clin Cancer Res. 2019;38(1):467.","journal-title":"J Exp Clin Cancer Res"},{"key":"3185_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-014-0284-y","author":"RB Koumangoye","year":"2015","unstructured":"Koumangoye RB, Andl T, Taubenslag KJ, et al. SOX4 interacts with EZH2 and HDAC3 tosuppress microRNA-31 in invasive esophageal cancer cells. Mol Cancer. 2015. https:\/\/doi.org\/10.1186\/s12943-014-0284-y.","journal-title":"Mol Cancer"},{"key":"3185_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/47412","volume":"403","author":"BD Strahl","year":"2000","unstructured":"Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41\u20135.","journal-title":"Nature"},{"key":"3185_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrg3173","volume":"13","author":"EL Greer","year":"2012","unstructured":"Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13:343\u201357.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"3185_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13059-019-1870-5","volume":"20","author":"Z Zhao","year":"2019","unstructured":"Zhao Z, Shilatifard A. Epigenetic modifications of histones in cancer. Genome Biol. 2019;20(1):245.","journal-title":"Genome Biol"},{"issue":"4","key":"3185_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2354","volume":"11","author":"J Puppe","year":"2009","unstructured":"Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, et al. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res. 2009;11(4):R63.","journal-title":"Breast Cancer Res"},{"issue":"10","key":"3185_CR24","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.15252\/embr.201540244","volume":"16","author":"HJ Choi","year":"2015","unstructured":"Choi HJ, Park JH, Park M, Won HY, Joo HS, Lee CH, et al. UTX inhibits EMT-induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1. EMBO Rep. 2015;16(10):1288\u201398.","journal-title":"EMBO Rep"},{"issue":"2","key":"3185_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s11033-022-07982-1","volume":"50","author":"V Jurisic","year":"2023","unstructured":"Jurisic V, Obradovic J, Nikolic N, Javorac J, Perin B, Milasin J. Analyses of P16INK4a gene promoter methylation relative to molecular, demographic and clinical parameters characteristics in non-small cell lung cancer patients: a pilot study. Mol Biol Rep. 2023;50(2):971\u20139.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"3185_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12943-023-01786-y","volume":"22","author":"J Chen","year":"2023","unstructured":"Chen J, Hong JH, Huang Y, Liu S, Yin J, Deng P, Sun Y, Yu Z, Zeng X. etal. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer. Mol Cancer. 2023;22(1):85.","journal-title":"Mol Cancer"},{"issue":"4","key":"3185_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.gendis.2019.10.018","volume":"7","author":"R Wang","year":"2019","unstructured":"Wang R, Liu X. Epigenetic regulation of prostate cancer. Genes Dis. 2019;7(4):606\u201313.","journal-title":"Genes Dis"},{"issue":"12","key":"3185_CR28","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.3390\/cancers12123649","volume":"12","author":"C Lachat","year":"2020","unstructured":"Lachat C, Bruy\u00e8re D, Etcheverry A, Aubry M, Mosser J, Warda W, Herfs M, Hendrick E, Ferrand C. etal. EZH2 and KDM6B expressions are associated with specific epigenetic signatures during EMT in Non small cell lung carcinomas. Cancers (Basel). 2020;12(12):3649.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"3185_CR29","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3892\/ijo.2013.2062","volume":"43","author":"X Chen","year":"2013","unstructured":"Chen X, Song N, Matsumoto K, Nanashima A, Nagayasu T, Hayashi T, et al. High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer. Int J Oncol. 2013;43(5):1467\u201380.","journal-title":"Int J Oncol"},{"issue":"2","key":"3185_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.yexcr.2017.08.024","volume":"359","author":"N Yan","year":"2017","unstructured":"Yan N, Xu L, Wu X, Zhang L, Fei X, Cao Y, Zhang F. GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells. Exp Cell Res. 2017;359(2):405\u201314.","journal-title":"Exp Cell Res"},{"issue":"22","key":"3185_CR31","doi-asserted-by":"publisher","first-page":"5849","DOI":"10.1158\/0008-5472.CAN-18-3511","volume":"79","author":"BJ Hong","year":"2019","unstructured":"Hong BJ, Park WY, Kim HR, Moon JW, Lee HY, Park JH, Kim SK, Oh Y, Roe JS. etal. Oncogenic KRAS sensitizes lung adenocarcinoma to GSK-J4-Induced metabolic and oxidative stress. Cancer Res. 2019;79(22):5849\u201359.","journal-title":"Cancer Res"},{"issue":"2","key":"3185_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41389-021-00307-0","volume":"10","author":"SH Lee","year":"2021","unstructured":"Lee SH, Kim O, Kim HJ, Hwangbo C, Lee JH. Epigenetic regulation of TGF-\u03b2-induced EMT by JMJD3\/KDM6B histone H3K27 demethylase. Oncogenesis. 2021;10(2):17.","journal-title":"Oncogenesis"},{"issue":"11","key":"3185_CR33","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.21873\/anticanres.11198","volume":"36","author":"H Watarai","year":"2016","unstructured":"Watarai H, Okada M, Kuramoto K, Takeda H, Sakaki H, Suzuki S, Seino S, Oizumi H, Sadahiro M. etal. Impact of H3K27 demethylase inhibitor GSKJ4 on NSCLC cells alone and in combination with Metformin. Anticancer Res. 2016;36(11):6083\u201392.","journal-title":"Anticancer Res"},{"issue":"22","key":"3185_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206798","volume":"10","author":"C Zheng","year":"2023","unstructured":"Zheng C, Zhang B, Li Y, Liu K, Wei W, Liang S, et al. Donafenib and GSK-J4 synergistically induce ferroptosis in liver cancer by upregulating HMOX1 expression. Adv Sci. 2023;10(22):e2206798.","journal-title":"Adv Sci"},{"issue":"3","key":"3185_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.21873\/cgp.20324","volume":"19","author":"A Sanchez","year":"2022","unstructured":"Sanchez A, Penault-Llorca F, Bignon YJ, Guy L, Bernard-Gallon D. Effects of GSK-J4 on JMJD3 histone demethylase in mouse prostate cancer xenografts. Cancer Genomics Proteomics. 2022;19(3):339\u201349.","journal-title":"Cancer Genomics Proteomics"},{"issue":"1","key":"3185_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12935-024-03231-6","volume":"24","author":"V Pecci","year":"2024","unstructured":"Pecci V, Troisi F, Aiello A, De Martino S, Carlino A, Fiorentino V, Ripoli C, Rotili D, Pierconti F. etal. Targeting of H19\/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer. Cancer Cell Int. 2024;24(1):56.","journal-title":"Cancer Cell Int"},{"issue":"22","key":"3185_CR37","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.7150\/thno.47081","volume":"10","author":"J Zhang","year":"2020","unstructured":"Zhang J, Ying Y, Li M, et al. Targeted inhibition of KDM6 histone demethylases eradicatestumor-initiating cells via enhancer reprogramming in colorectal cancer. Theranostics. 2020;10(22):10016\u201330.","journal-title":"Theranostics"},{"key":"3185_CR38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3389\/fphar.2020.00632","volume":"11","author":"B Lin","year":"2020","unstructured":"Lin B, Lu B, Hsieh IY, Liang Z, Sun Z, Yi Y, Lv W, Zhao W, Li J. Synergy of GSK-J4 with doxorubicin in KRAS-Mutant anaplastic thyroid cancer. Front Pharmacol. 2020;11:632.","journal-title":"Front Pharmacol"},{"key":"3185_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12935-020-01297-6","volume":"20","author":"X Chu","year":"2020","unstructured":"Chu X, Zhong L, Yu L, Xiong L, Li J, Dan W, Ye J, Liu C, Luo X. etal. GSK-J4 induces cell cycle arrest and apoptosis via ER stress and the synergism between GSK-J4 and decitabine in acute myeloid leukemia KG-1a cells. Cancer Cell Int. 2020;20:209.","journal-title":"Cancer Cell Int"},{"issue":"37","key":"3185_CR40","doi-asserted-by":"publisher","first-page":"62131","DOI":"10.18632\/oncotarget.19100","volume":"8","author":"VM Morozov","year":"2017","unstructured":"Morozov VM, Li Y, Clowers MM, Ishov AM. Inhibitor of H3K27 demethylase JMJD3\/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer. Oncotarget. 2017;8(37):62131\u201342.","journal-title":"Oncotarget"},{"issue":"1","key":"3185_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.canlet.2004.05.011","volume":"214","author":"V Jurisi\u0107","year":"2004","unstructured":"Jurisi\u0107 V, Bogdanovic G, Srdic T, Jakimov D, Mrdjanovic J, Baltic M, Baltic VV. Modulation of TNF-alpha activity in tumor PC cells using anti-CD45 and anti-CD95 monoclonal antibodies. Cancer Lett. 2004;214(1):55\u201361.","journal-title":"Cancer Lett"},{"issue":"2","key":"3185_CR42","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.1016\/0167-8760(88)90038-4","volume":"6","author":"JL Andreassi","year":"1988","unstructured":"Andreassi JL. Psychophysiological research: a contemporary perspective. Int J Psychophysiol. 1988;6(2):iii\u2013vi.","journal-title":"Int J Psychophysiol"},{"issue":"3","key":"3185_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00232-010-9309-7","volume":"239","author":"V Jurisic","year":"2011","unstructured":"Jurisic V, Srdic-Rajic T, Konjevic G, Bogdanovic G, Colic M. TNF-\u03b1 induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol. 2011;239(3):115\u201322.","journal-title":"J Membr Biol"},{"issue":"11","key":"3185_CR44","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1161\/ATVBAHA.120.315214","volume":"40","author":"OH Liu","year":"2020","unstructured":"Liu OH, Kiema M, Beter M, Yl\u00e4-Herttuala S, Laakkonen JP, Kaikkonen MU. Hypoxia-mediated regulation of histone demethylases affects Angiogenesis-Associated functions in endothelial cells. Arterioscler Thromb Vasc Biol. 2020;40(11):2665\u201377.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3185_CR45","doi-asserted-by":"publisher","first-page":"842295","DOI":"10.3389\/fphar.2022.842295","volume":"13","author":"H Ge","year":"2022","unstructured":"Ge H, Xu C, Chen H, Liu L, Zhang L, Wu C, et al. Traditional Chinese medicines as effective reversals of epithelial-mesenchymal transition induced-metastasis of colorectal cancer: molecular targets and mechanisms. Front Pharmacol. 2022;13:842295.","journal-title":"Front Pharmacol"},{"issue":"18","key":"3185_CR46","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.3390\/ijms21186873","volume":"21","author":"HY Cho","year":"2020","unstructured":"Cho HY, Lee SW, Jeon YH, Lee DH, Kim GW, Yoo J, Kim SY, Kwon SH. Combination of ACY-241 and JQ1 synergistically suppresses metastasis of HNSCC via regulation of MMP-2 and MMP-9. Int J Mol Sci. 2020;21(18):6873.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3185_CR47","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/14789450.2020.1845654","volume":"17","author":"V Jurisic","year":"2020","unstructured":"Jurisic V. Multiomic analysis of cytokines in immuno-oncology. Expert Rev Proteomics. 2020;17(9):663\u201374.","journal-title":"Expert Rev Proteomics"},{"issue":"3","key":"3185_CR48","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212\u201326.","journal-title":"Trends Cell Biol"},{"issue":"344","key":"3185_CR49","doi-asserted-by":"publisher","first-page":"re8","DOI":"10.1126\/scisignal.2005189","volume":"7","author":"DM Gonzalez","year":"2014","unstructured":"Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014;7(344):re8.","journal-title":"Sci Signal"},{"issue":"2","key":"3185_CR50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrc.2017.118","volume":"18","author":"T Brabletz","year":"2018","unstructured":"Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18(2):128\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"3185_CR51","doi-asserted-by":"publisher","first-page":"e0232917","DOI":"10.1371\/journal.pone.0232917","volume":"15","author":"KY Park","year":"2020","unstructured":"Park KY, Kim J. Cyclic pentapeptide cRGDfK enhances the inhibitory effect of Sunitinib on TGF-\u03b21-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells. PLoS One. 2020;15(8):e0232917.","journal-title":"PLoS One"},{"issue":"4","key":"3185_CR52","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","volume":"48","author":"JC Black","year":"2012","unstructured":"Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012;48(4):491\u2013507.","journal-title":"Mol Cell"},{"issue":"5","key":"3185_CR53","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrg3173","volume":"13","author":"EL Greer","year":"2012","unstructured":"Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13(5):343\u201357.","journal-title":"Nat Rev Genet"},{"issue":"5","key":"3185_CR54","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.molcel.2016.05.029","volume":"62","author":"JP Etchegaray","year":"2016","unstructured":"Etchegaray JP, Mostoslavsky R. Interplay between metabolism and epigenetics: a nuclear adaptation to environmental changes. Mol Cell. 2016;62(5):695\u2013711.","journal-title":"Mol Cell"},{"key":"3185_CR55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.csbj.2018.06.001","volume":"16","author":"Y Chen","year":"2018","unstructured":"Chen Y, Liu X, Li Y, Quan C, Zheng L, Huang K. Lung cancer therapy targeting histone methylation: opportunities and challenges. Comput Struct Biotechnol J. 2018;16:211\u201323.","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"3185_CR56","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1124\/dmd.116.073734","volume":"45","author":"Q Yu","year":"2017","unstructured":"Yu Q, Liu Y, Zheng X, Zhu Q, Shen Z, Wang H, et al. Histone H3 lysine 4 trimethylation, lysine 27 trimethylation, and lysine 27 acetylation contribute to the transcriptional repression of solute carrier family 47 member 2 in renal cell carcinoma. Drug Metab Dispos. 2017;45(1):109\u201317.","journal-title":"Drug Metab Dispos"},{"issue":"16","key":"3185_CR57","doi-asserted-by":"publisher","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b00855","volume":"59","author":"X Yang","year":"2016","unstructured":"Yang X, Li F, Konze KD, Meslamani J, Ma A, Brown PJ, Zhou MM, Arrowsmith CH, Kaniskan H\u00dc. etal. Structure-Activity relationship studies for enhancer of Zeste homologue 2 (EZH2) and enhancer of Zeste homologue 1 (EZH1) inhibitors. J Med Chem. 2016;59(16):7617\u201333.","journal-title":"J Med Chem"},{"issue":"5","key":"3185_CR58","first-page":"6179","volume":"15","author":"K Zhu","year":"2018","unstructured":"Zhu K, Deng Y, Weng G, Hu D, Huang C, Matsumoto K, Nagayasu T, Koji T, Zheng X. etal. Analysis of H3K27me3 expression and DNA methylation at CCGG sites in smoking and non-smoking patients with non-small cell lung cancer and their clinical significance. Oncol Lett. 2018;15(5):6179\u201388.","journal-title":"Oncol Lett"},{"key":"3185_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154071","volume":"238","author":"T Onishi","year":"2022","unstructured":"Onishi T, Takashima T, Kurashige M, Ohshima K, Morii E. Mutually exclusive expression of EZH2 and H3K27me3 in non-small cell lung carcinoma. Pathol Res Pract. 2022;238:154071.","journal-title":"Pathol Res Pract"},{"issue":"3","key":"3185_CR60","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.celrep.2016.06.034","volume":"16","author":"M Hosogane","year":"2016","unstructured":"Hosogane M, Funayama R, Shirota M, Nakayama K. Lack of transcription triggers H3K27me3 accumulation in the gene body. Cell Rep. 2016;16(3):696\u2013706.","journal-title":"Cell Rep"},{"issue":"1","key":"3185_CR61","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13148-022-01305-8","volume":"14","author":"J Abu-Hanna","year":"2022","unstructured":"Abu-Hanna J, Patel JA, Anastasakis E, Cohen R, Clapp LH, Loizidou M, Eddama MMR. Therapeutic potential of inhibiting histone 3 lysine 27 demethylases: a review of the literature. Clin Epigenetics. 2022;14(1):98.","journal-title":"Clin Epigenetics"},{"key":"3185_CR62","first-page":"5752263","volume":"2022","author":"X Chen","year":"2022","unstructured":"Chen X, Deng Y, Huang C, Shi Y, Lu J, Weng G, Zhu W, Zhu K, Chen J. etal. RUNX3\/H3K27me3 Co-Expression defines a better prognosis in surgically resected stage I and postoperative Chemotherapy-Naive Non-Small-Cell lung cancer. J Oncol. 2022;2022:5752263.","journal-title":"J Oncol"},{"issue":"19","key":"3185_CR63","doi-asserted-by":"publisher","first-page":"11911","DOI":"10.3390\/ijms231911911","volume":"23","author":"JCC Lesbon","year":"2022","unstructured":"Lesbon JCC, Garnica TK, Xavier PLP, Rochetti AL, Reis RM, M\u00fcller S, Fukumasu H. A screening of epigenetic therapeutic targets for Non-Small cell lung cancer reveals PADI4 and KDM6B as promising candidates. Int J Mol Sci. 2022;23(19):11911.","journal-title":"Int J Mol Sci"},{"issue":"29","key":"3185_CR64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2401834121","volume":"121","author":"L Shan","year":"2024","unstructured":"Shan L, Wang W, Du L, Li D, Wang Y, Xie Y, et al. SP1 undergoes phase separation and activates RGS20 expression through super-enhancers to promote lung adenocarcinoma progression. Proc Natl Acad Sci U S A. 2024;121(29):e2401834121. https:\/\/doi.org\/10.1073\/pnas.2401834121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"3185_CR65","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00432-018-2631-7","volume":"144","author":"Y Li","year":"2018","unstructured":"Li Y, Zhang M, Sheng M, Zhang P, Chen Z, Xing W, et al. Therapeutic potential of GSK-J4, a histone demethylase KDM6B\/JMJD3 inhibitor, for acute myeloid leukemia. J Cancer Res Clin Oncol. 2018;144(6):1065\u201377.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"441","key":"3185_CR66","doi-asserted-by":"publisher","first-page":"eaao4680","DOI":"10.1126\/scitranslmed.aao4680","volume":"10","author":"TL Lochmann","year":"2018","unstructured":"Lochmann TL, Powell KM, Ham J, Floros KV, Heisey DAR, Kurupi RIJ, Calbert ML, Ghotra MS, Greninger P. etal. Targeted Inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. Sci Transl Med. 2018;10(441):eaao4680.","journal-title":"Sci Transl Med"},{"issue":"2","key":"3185_CR67","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1167\/iovs.65.2.34","volume":"65","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wu W, Xu C, Yang H, Huang G. Antitumoral potential of the histone demethylase inhibitor GSK-J4 in retinoblastoma. Invest Ophthalmol Vis Sci. 2024;65(2):34.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"3185_CR68","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13148-024-01665-3","volume":"16","author":"D Chen","year":"2024","unstructured":"Chen D, Cai B, Zhu Y, Ma Y, Yu X, Xiong J, Shen J, Tie W, Zhang Y. etal. Targeting histone demethylases JMJD3 and UTX: selenium as a potential therapeutic agent for cervical cancer. Clin Epigenetics. 2024;16(1):51.","journal-title":"Clin Epigenetics"},{"issue":"18","key":"3185_CR69","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1158\/1078-0432.CCR-18-3890","volume":"25","author":"H Katagi","year":"2019","unstructured":"Katagi H, Louis N, Unruh D, Sasaki T, He X, Zhang A, et al. Radiosensitization by histone H3 demethylase inhibition in diffuse intrinsic Pontine glioma. Clin Cancer Res. 2019;25(18):5572\u201383.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3185_CR70","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/jmcb\/mjz032","volume":"12","author":"Q Wang","year":"2020","unstructured":"Wang Q, Chen X, Jiang Y, Liu S, Liu H, Sun X, Zhang H, Liu Z, Tao Y. etal. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin. J Mol Cell Biol. 2020;12(2):125\u201337.","journal-title":"J Mol Cell Biol"},{"issue":"18","key":"3185_CR71","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1158\/1078-0432.CCR-18-3890","volume":"25","author":"H Katagi","year":"2019","unstructured":"Katagi H, Louis N, Unruh D, Sasaki T, He X, Zhang A, Ma Q, Piunti A, Shimazu Y. etal. Radiosensitization by histone H3 demethylase Inhibition in diffuse intrinsic Pontine glioma. Clin Cancer Res. 2019;25(18):5572\u201383.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3185_CR72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, Zhou Z, Shu G, Yin G. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"3185_CR73","doi-asserted-by":"publisher","first-page":"a015081","DOI":"10.1101\/cshperspect.a015081","volume":"5","author":"CM Cruciat","year":"2013","unstructured":"Cruciat CM, Niehrs C. Secreted and transmembrane Wnt inhibitors and activators. Cold Spring Harb Perspect Biol. 2013;5(3):a015081.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"3185_CR74","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-021-00701-5","volume":"6","author":"F Yu","year":"2021","unstructured":"Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, Wu C, Wang C, Ye L. Wnt\/\u03b2-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6(1):307.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"3185_CR75","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41575-018-0075-9","volume":"16","author":"MJ Perugorria","year":"2019","unstructured":"Perugorria MJ, Olaizola P, Labiano I, Esparza-Baquer A, Marzioni M, Marin JJG, Bujanda L, Banales JM. Wnt-\u03b2-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2019;16(2):121\u201336.","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03185-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03185-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03185-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:04:30Z","timestamp":1770393870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03185-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":75,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["3185"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03185-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"This animal study was reviewed and approved by the Medical Ethics Committee of the Second Affiliated Hospital of Harbin Medical University (YJSDW2023-023).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"86"}}